Celyad Oncology is a biotechnology company based in Boston, MA, dedicated to the research and development of chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. They focus on advancing both allogeneic and autologous CAR T-cell therapy candidates, utilizing their broad understanding of immunology, novel technology platforms, and modular design approach to drug discovery.
With a commitment to next-generation cellular immunotherapies, Celyad Oncology aims to revolutionize cancer treatment by harnessing the power of CAR T-cell therapy and delivering innovative solutions to patients in need.
Generated from the website